IDEXX Laboratories Company Profile (NASDAQ:IDXX)

About IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories logoIDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Veterinary Medical Equipment & Supplies
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:IDXX
  • CUSIP: 45168D10
  • Web:
  • Market Cap: $13.34 billion
  • Outstanding Shares: 87,275,000
Average Prices:
  • 50 Day Moving Avg: $159.83
  • 200 Day Moving Avg: $157.39
  • 52 Week Range: $102.45 - $173.01
  • Trailing P/E Ratio: 51.74
  • Foreward P/E Ratio: 43.17
  • P/E Growth: 2.50
Sales & Book Value:
  • Annual Revenue: $1.86 billion
  • Price / Sales: 7.17
  • Book Value: ($0.99) per share
  • Price / Book: -154.36
  • EBIDTA: $467.99 million
  • Net Margins: 14.13%
  • Return on Equity: -473.46%
  • Return on Assets: 16.18%
  • Debt-to-Equity Ratio: -6.98%
  • Current Ratio: 0.92%
  • Quick Ratio: 0.75%
  • Average Volume: 623,000 shs.
  • Beta: 0.49
  • Short Ratio: 4.18

Frequently Asked Questions for IDEXX Laboratories (NASDAQ:IDXX)

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories declared that its board has approved a stock repurchase plan on Sunday, June 4th 2017, which allows the company to repurchase 3,000,000 outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its earnings results on Tuesday, August, 1st. The company reported $0.95 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.85 by $0.10. The company had revenue of $508.90 million for the quarter, compared to the consensus estimate of $502.44 million. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The firm's quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.74 EPS. View IDEXX Laboratories' Earnings History.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY17 earnings guidance on Tuesday, August, 1st. The company provided earnings per share (EPS) guidance of $3.12-3.22 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.07. The company issued revenue guidance of $1.945-1.965 billion, compared to the consensus revenue estimate of $1.94 billion.

Where is IDEXX Laboratories' stock going? Where will IDEXX Laboratories' stock price be in 2017?

6 brokers have issued 1-year price objectives for IDEXX Laboratories' shares. Their forecasts range from $118.00 to $200.00. On average, they anticipate IDEXX Laboratories' stock price to reach $170.75 in the next year. View Analyst Ratings for IDEXX Laboratories.

What are analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:

  • 1. According to Zacks Investment Research, "IDEXX continues to demonstrate solid growth globally with strong international expansion. Management’s innovation-based global strategy is leading to its CAG Diagnostics growth. Solid organic revenue growth buoys optimism. Moreover, the company recently expanded its cloud technology portfolio by adding rVetLink to it. IDEXX’s last reported first quarter was also impressive with earnings and revenues growing year over year. The raised 2017 EPS guidance is also encouraging. Notably,  over the last six months, the company has been trading above the broader Medical Instruments industry. On the other hand, IDEXX's high dependence on third-party distributors and intense competition continue to pose threats. Moreover, with growing international expansion, the company's Companion Animal Diagnostics business is likely to suffer from adverse currency fluxes. The stock’s overvaluation also remains a concern." (7/19/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)

Who are some of IDEXX Laboratories' key competitors?

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:

  • Jonathan W. Ayers, Chairman of the Board, President, Chief Executive Officer
  • Brian P. McKeon, Chief Financial Officer, Executive Vice President, Treasurer
  • Giovani Twigge, Chief Human Resource Officer, Corporate Vice President
  • Jay Mazelsky, Executive Vice President
  • Jacqueline L. Studer, Corporate Vice President, General Counsel, Corporate Secretary
  • William T. End, Lead Independent Director
  • Bruce L. Claflin, Independent Director
  • Stuart M. Essig Ph.D., Independent Director
  • Rebecca M. Henderson Ph.D., Independent Director
  • Daniel M. Junius, Independent Director

Who owns IDEXX Laboratories stock?

IDEXX Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.62%), BlackRock Inc. (8.14%), Bamco Inc. NY (5.42%), Fundsmith LLP (5.09%), State Street Corp (4.39%) and Blair William & Co. IL (2.04%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Who sold IDEXX Laboratories stock? Who is selling IDEXX Laboratories stock?

IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Atlanta Capital Management Co. L L C, JPMorgan Chase & Co., Fiera Capital Corp, Bamco Inc. NY, Neuberger Berman Group LLC, Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado and Prudential Financial Inc.. Company insiders that have sold IDEXX Laboratories stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Rebecca M Henderson, Thomas Craig and William T End. View Insider Buying and Selling for IDEXX Laboratories.

Who bought IDEXX Laboratories stock? Who is buying IDEXX Laboratories stock?

IDEXX Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Koch Industries Inc., Janus Henderson Group PLC, BlackRock Inc., Old Mutual Global Investors UK Ltd., Arrowstreet Capital Limited Partnership, Renaissance Technologies LLC, Goldman Sachs Group Inc. and Vanguard Group Inc.. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy IDEXX Laboratories stock?

Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDEXX Laboratories stock can currently be purchased for approximately $152.82.

MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  348
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for IDEXX Laboratories (NASDAQ:IDXX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.17)
Consensus Price Target: $170.75 (11.73% upside)

Analysts' Ratings History for IDEXX Laboratories (NASDAQ:IDXX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/21/2017Stifel NicolausReiterated RatingBuy$185.00LowView Rating Details
7/28/2017CL KingUpgradeNeutral -> Buy$200.00MediumView Rating Details
6/13/2017Canaccord GenuityReiterated RatingBuy$180.00LowView Rating Details
5/31/2017AegisInitiated CoverageSell$118.00LowView Rating Details
2/3/2017Feltl & Co.DowngradeHold -> SellN/AView Rating Details
9/29/2016Bank of America CorporationReiterated RatingNeutralN/AView Rating Details
8/3/2016Northcoast ResearchUpgradeSell -> NeutralN/AView Rating Details
4/13/2016Credit Suisse GroupBoost Price TargetOutperform$80.00 -> $85.00N/AView Rating Details
2/1/2016Piper Jaffray CompaniesReiterated RatingNeutral$73.00 -> $75.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
8/28/2015Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 8/22/2015 forward)


Earnings History for IDEXX Laboratories (NASDAQ:IDXX)
Earnings by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Earnings History by Quarter for IDEXX Laboratories (NASDAQ IDXX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017Q2 2017$0.85$0.95$502.44 million$508.90 millionViewListenView Earnings Details
4/28/2017Q1 17$0.61$0.77$455.10 million$462.00 millionViewN/AView Earnings Details
2/2/2017Q416$0.51$0.58$436.07 million$443.00 millionViewListenView Earnings Details
11/1/2016Q316$0.59$0.62$448.60 million$448.30 millionViewListenView Earnings Details
8/2/2016Q216$0.62$0.74$444.83 million$467.00 millionViewListenView Earnings Details
4/29/2016Q116$0.47$0.51$403.48 million$417.55 millionViewListenView Earnings Details
1/29/2016Q415$0.44$0.48$397.39 million$400.00 millionViewListenView Earnings Details
10/28/2015Q315$0.53$0.54$409.33 million$406.00 millionViewListenView Earnings Details
7/30/2015Q215$0.57$0.60$412.57 million$413.30 millionViewListenView Earnings Details
4/28/2015Q115$0.98$0.98$394.38 million$382.00 millionViewN/AView Earnings Details
1/30/2015Q414$0.80$0.95$373.20 million$352.00 millionViewN/AView Earnings Details
10/24/2014Q314$0.90$1.05$371.80 million$384.00 millionViewListenView Earnings Details
7/25/2014Q214$1.06$1.10$385.20 million$390.00 millionViewN/AView Earnings Details
4/25/2014Q114$0.87$0.89$361.58 million$360.20 millionViewListenView Earnings Details
2/4/2014Q413$0.81$0.82$347.08 million$354.10 millionViewN/AView Earnings Details
10/22/2013Q313$0.83$0.86$339.70 million$338.30 millionViewN/AView Earnings Details
7/23/2013Q2 2013$0.97$0.99$356.80 million$352.60 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.83$0.81$341.06 million$332.10 millionViewN/AView Earnings Details
1/29/2013Q4 2012$0.71$0.78$325.10 million$319.50 millionViewN/AView Earnings Details
10/19/2012$0.73$0.76ViewN/AView Earnings Details
7/20/2012$0.90$0.91ViewN/AView Earnings Details
4/20/2012$0.71$0.72ViewN/AView Earnings Details
1/27/2012$0.63$0.67ViewN/AView Earnings Details
10/21/2011$0.65$0.66ViewN/AView Earnings Details
7/22/2011$0.72$0.83ViewN/AView Earnings Details
4/21/2011$0.59$0.62ViewN/AView Earnings Details
1/28/2011$0.55$0.62ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for IDEXX Laboratories (NASDAQ:IDXX)
2017 EPS Consensus Estimate: $2.88
2018 EPS Consensus Estimate: $3.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.59$0.61$0.60
Q2 20173$0.82$0.88$0.85
Q3 20173$0.74$0.75$0.75
Q4 20173$0.67$0.72$0.69
Q1 20181$0.78$0.78$0.78
Q2 20181$1.10$1.10$1.10
Q3 20181$0.83$0.83$0.83
Q4 20181$0.82$0.82$0.82
(Data provided by Zacks Investment Research)


Dividend History for IDEXX Laboratories (NASDAQ:IDXX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for IDEXX Laboratories (NASDAQ:IDXX)
Insider Ownership Percentage: 2.77%
Institutional Ownership Percentage: 89.42%
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2017Jonathan W AyersChairmanSell58,000$155.00$8,990,000.00View SEC Filing  
8/15/2017Jonathan W AyersCEOSell20,000$154.62$3,092,400.00View SEC Filing  
8/14/2017Jonathan W AyersCEOSell18,000$154.91$2,788,380.00View SEC Filing  
8/9/2017Jonathan W AyersChairmanSell17,000$154.54$2,627,180.00View SEC Filing  
8/8/2017Jonathan W. AyersChairmanSell18,000$155.22$2,793,960.00View SEC Filing  
8/3/2017Lawrence D KingsleyDirectorBuy2,000$151.76$303,520.00View SEC Filing  
5/31/2017Giovani TwiggeInsiderSell2,572$166.90$429,266.80View SEC Filing  
5/30/2017Jonathan W AyersChairmanSell13,000$167.82$2,181,660.00View SEC Filing  
5/22/2017William T EndDirectorSell5,000$162.55$812,750.00View SEC Filing  
5/10/2017Jonathan W AyersChairmanSell27,000$162.69$4,392,630.00View SEC Filing  
5/5/2017Jonathan W. AyersChairmanSell26,000$160.61$4,175,860.00View SEC Filing  
5/4/2017Rebecca M HendersonDirectorSell1,700$159.95$271,915.00View SEC Filing  
3/1/2017Lawrence D KingsleyDirectorBuy1,000$146.48$146,480.00View SEC Filing  
2/22/2017Jonathan W AyersChairmanSell35,000$142.58$4,990,300.00View SEC Filing  
2/8/2017Brian P MckeonVPSell9,924$141.64$1,405,635.36View SEC Filing  
2/8/2017Daniel M JuniusDirectorSell3,000$141.75$425,250.00View SEC Filing  
2/8/2017Jonathan W. AyersChairmanSell36,250$141.63$5,134,087.50View SEC Filing  
11/29/2016Jonathan W AyersChairmanSell27,424$119.77$3,284,572.48View SEC Filing  
11/28/2016Jonathan W AyersCEOSell13,188$119.57$1,576,889.16View SEC Filing  
11/23/2016Thomas CraigDirectorSell8,500$120.06$1,020,510.00View SEC Filing  
11/9/2016Jonathan W. AyersChairmanSell40,000$107.85$4,314,000.00View SEC Filing  
11/8/2016William T EndDirectorSell5,000$109.87$549,350.00View SEC Filing  
8/25/2016Rebecca M HendersonDirectorSell9,924$110.43$1,095,907.32View SEC Filing  
8/15/2016Barry C JohnsonDirectorSell9,924$111.37$1,105,235.88View SEC Filing  
8/8/2016Michael J. Phd WilliamsInsiderSell49,560$108.94$5,399,066.40View SEC Filing  
8/5/2016William T EndDirectorSell5,000$108.50$542,500.00View SEC Filing  
8/4/2016Jonathan W. AyersChairmanSell60,000$107.69$6,461,400.00View SEC Filing  
5/5/2016William T EndDirectorSell4,924$85.87$422,823.88View SEC Filing  
2/24/2016Michael J Phd WilliamsEVPSell2,000$71.93$143,860.00View SEC Filing  
2/9/2016Thomas CraigDirectorSell2,054$69.52$142,794.08View SEC Filing  
2/8/2016Brian P. MckeonCFOSell9,054$69.65$630,611.10View SEC Filing  
11/30/2015Thomas CraigDirectorSell7,000$70.28$491,960.00View SEC Filing  
11/12/2015Rebecca M. HendersonDirectorSell2,300$68.39$157,297.00View SEC Filing  
8/31/2015Thomas CraigDirectorSell800$71.77$57,416.00View SEC Filing  
8/18/2015Michael J. Phd WilliamsEVPSell6,586$78.34$515,947.24View SEC Filing  
8/18/2015Thomas CraigDirectorSell2,900$79.41$230,289.00View SEC Filing  
8/17/2015Jonathan W AyersCEOSell14,799$78.45$1,160,981.55View SEC Filing  
5/18/2015William T EndDirectorSell3,527$134.51$474,416.77View SEC Filing  
3/10/2015William T EndDirectorSell3,500$150.89$528,115.00View SEC Filing  
3/4/2015Johnny D PowersEVPSell6,168$158.49$977,566.32View SEC Filing  
2/17/2015Brian P MckeonCFOSell5,000$156.99$784,950.00View SEC Filing  
2/12/2015Jonathan W AyersCEOSell58,245$155.45$9,054,185.25View SEC Filing  
2/5/2015Rebecca M HendersonDirectorSell2,934$156.27$458,496.18View SEC Filing  
2/4/2015Thomas CraigDirectorSell2,200$157.02$345,444.00View SEC Filing  
1/14/2015Jonathan W AyersCEOSell28,512$157.68$4,495,772.16View SEC Filing  
12/3/2014Jonathan W AyersCEOSell29,000$148.49$4,306,210.00View SEC Filing  
11/13/2014Thomas CraigDirectorSell5,000$152.45$762,250.00View SEC Filing  
11/5/2014Jonathan W AyersCEOSell29,000$143.45$4,160,050.00View SEC Filing  
11/4/2014Johnny D PowersEVPSell1,292$142.70$184,368.40View SEC Filing  
8/13/2014M Anne SzostakDirectorBuy2,000$127.03$254,060.00View SEC Filing  
2/20/2014M Anne SzostakDirectorBuy2,000$126.71$253,420.00View SEC Filing  
2/19/2014Thomas CraigDirectorSell4,800$125.42$602,016.00View SEC Filing  
2/3/2014Jonathan AyersCEOSell81,294$112.46$9,142,323.24View SEC Filing  
11/26/2013Jonathan AyersCEOSell78,178$105.29$8,231,361.62View SEC Filing  
11/22/2013Sophie VandebroekDirectorBuy1,000$107.84$107,840.00View SEC Filing  
11/13/2013Jonathan AyersCEOSell78,178$106.36$8,315,012.08View SEC Filing  
11/4/2013M Anne SzostakDirectorBuy1,000$108.24$108,240.00View SEC Filing  
11/4/2013Michael Phd WilliamsEVPSell6,020$108.19$651,303.80View SEC Filing  
10/31/2013William T EndDirectorSell2,500$108.32$270,800.00View SEC Filing  
10/25/2013Jonathan W AyersCEOSell78,178$104.36$8,158,656.08View SEC Filing  
9/13/2013Johnny PowersEVPSell13,128$96.59$1,268,033.52View SEC Filing  
9/5/2013Michael J Phd WilliamsEVPSell5,162$95.58$493,383.96View SEC Filing  
5/9/2013Ali NaquiVPSell12,961$87.00$1,127,607.00View SEC Filing  
2/4/2013Merilee RainesCFOSell175,929$94.25$16,581,308.25View SEC Filing  
11/13/2012Jonathan W AyersCEOSell15,000$89.92$1,348,800.00View SEC Filing  
9/5/2012Johnny D PowersEVPSell4,000$97.12$388,480.00View SEC Filing  
8/8/2012Merilee RainesCFOSell7,726$88.84$686,377.84View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for IDEXX Laboratories (NASDAQ:IDXX)
Latest Headlines for IDEXX Laboratories (NASDAQ:IDXX)
DateHeadline logoHere's Why You Must Add Chemed (CHE) Stock to Your Portfolio - Nasdaq - August 21 at 6:59 PM logoIDEXX Laboratories' (IDXX) "Buy" Rating Reiterated at Stifel Nicolaus - August 21 at 12:02 PM logoQ3 2017 Earnings Estimate for IDEXX Laboratories, Inc. Issued By William Blair (IDXX) - August 21 at 2:54 AM logoIDEXX Laboratories, Inc. (IDXX) Receives Consensus Rating of "Hold" from Analysts - August 19 at 3:16 PM logoGlobus Medical's Robotic Guidance System Gets FDA Approval - Nasdaq - August 19 at 12:39 AM logoIdexx Laboratories Inc (IDXX) Chairman, President & CEO Jonathan W Ayers Sold $9 million of ... - Nasdaq - August 19 at 12:39 AM logoHere's Why You Should Invest in IDEXX Laboratories (IDXX) Now - August 18 at 5:17 AM logoIdexx Laboratories Inc (IDXX) Chairman, President & CEO Jonathan W Ayers Sold $9 million of ... - August 18 at 5:17 AM logoInsider Selling: IDEXX Laboratories, Inc. (IDXX) CEO Sells 18,000 Shares of Stock - August 16 at 10:26 PM logoInsider Selling: IDEXX Laboratories, Inc. (IDXX) CEO Sells 20,000 Shares of Stock - August 16 at 10:26 PM logoJonathan W. Ayers Sells 58,000 Shares of IDEXX Laboratories, Inc. (IDXX) Stock - August 16 at 10:26 PM logoIDEXX Laboratories, Inc. – Value Analysis (NASDAQ:IDXX) : August 12, 2017 - August 12 at 1:15 AM logoInsider Selling: IDEXX Laboratories, Inc. (NASDAQ:IDXX) Chairman Sells 17,000 Shares of Stock - August 10 at 10:38 PM logo$493.63 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter - August 10 at 5:16 PM logoSee what the IHS Markit Score report has to say about Idexx Laboratories Inc. - August 10 at 5:59 AM logoFresenius Medical Inks $2B Deal to Take Over NxStage Medical ... - Nasdaq - August 9 at 7:58 PM logoJonathan W. Ayers Sells 18,000 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock - August 9 at 7:34 PM logoIDEXX Laboratories to Host 2017 Investor Day - August 8 at 7:27 PM logoZacks: Analysts Expect IDEXX Laboratories, Inc. (IDXX) Will Announce Earnings of $0.75 Per Share - August 8 at 7:32 AM logoInsider Buying: IDEXX Laboratories, Inc. (IDXX) Director Buys 2,000 Shares of Stock - August 4 at 8:22 PM logoMillennials are taking pet owning 'to a whole new level,'... - August 4 at 12:57 AM logoIDEXX Laboratories results: The raw numbers - Motley Fool - August 3 at 7:54 PM logoIDEXX Laboratories: Cramer's Top Takeaways - August 3 at 7:54 PM logoNorthcoast Research Equities Analysts Lower Earnings Estimates for IDEXX Laboratories, Inc. (NASDAQ:IDXX) - August 3 at 8:28 AM logoIDEXX Laboratories, Inc. (IDXX) to Post Q3 2017 Earnings of $0.74 Per Share, William Blair Forecasts - August 3 at 8:28 AM logoIDEXX Laboratories Inc Reveals 27% Rise In Q2 Earnings - August 2 at 10:53 PM logoIDEXX Laboratories, Inc.'s Investors Look the Gift Horse in the Mouth - August 2 at 10:53 PM logoIDEXX Laboratories, Inc.'s Investors Look the Gift Horse in the Mouth - August 2 at 1:53 PM logoBrokers Issue Forecasts for IDEXX Laboratories, Inc.'s FY2017 Earnings (NASDAQ:IDXX) - August 2 at 10:38 AM logoIDEXX Laboratories, Inc. (IDXX) Expected to Post FY2017 Earnings of $3.13 Per Share - August 2 at 10:38 AM logoIDEXX Laboratories, Inc. (IDXX) Earns Buy Rating from Stifel Nicolaus - August 2 at 9:50 AM logoIDEXX Laboratories Q2 Profit Increases, Lifts FY17 Outlook - August 2 at 1:24 AM logoEdited Transcript of IDXX earnings conference call or presentation 1-Aug-17 12:30pm GMT - August 2 at 1:24 AM logoMarket Close Report: NASDAQ Composite index closes at 6362.94 up 14.82 points - Nasdaq - August 1 at 8:23 PM logoIDEXX Laboratories (IDXX) Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 1 at 3:21 PM logoInvestor Network: IDEXX Laboratories, Inc. to Host Earnings Call - August 1 at 3:21 PM logoIDEXX Laboratories Announces Second Quarter Results - August 1 at 3:21 PM logoIDEXX Laboratories (IDXX) Beats on Q2 Earnings & Revenues - August 1 at 3:21 PM logoIDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up - August 1 at 3:21 PM logoIdexx tops Street 2Q forecasts - August 1 at 3:21 PM logoIDEXX Laboratories, Inc. (IDXX) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS - August 1 at 10:47 AM logoIDEXX Laboratories, Inc. (IDXX) Updates FY17 Earnings Guidance - August 1 at 9:58 AM logoMedical Products Earnings Due on Aug 1: IDXX, RMD - Nasdaq - July 31 at 7:11 PM logoMedical Products Earnings Due on Aug 1: IDXX, RMD - July 31 at 7:11 PM logoIDEXX Laboratories, Inc. (NASDAQ:IDXX) Upgraded to "Buy" by CL King - July 30 at 10:36 AM logoWhy Earnings Season Could Be Great for IDEXX Laboratories (IDXX) - July 28 at 11:00 PM logoIDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : July 28, 2017 - July 28 at 11:00 PM logoMedTech Stocks to Top Q2 Estimates - Nasdaq - July 28 at 3:15 AM logoMedTech Stocks to Top Q2 Estimates - July 27 at 10:15 PM logoA Stock That Is Like Switzerland And Another One With A Very Compelling Razor/Razor Blade Model - July 25 at 8:04 PM



IDEXX Laboratories (IDXX) Chart for Tuesday, August, 22, 2017

This page was last updated on 8/22/2017 by Staff